We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · February 12, 2021

Botulinum Toxin Injected Into Intrinsic Laryngeal Muscles for Spasmodic Dysphonia

European Journal of Neurology


Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Neurology
Botulinum Toxin Injection Into the Intrinsic Laryngeal Muscles to Treat Spasmodic Dysphonia: A Multicenter, Placebo-Controlled, Randomized, Double-Blinded, Parallel-Group Comparison/Open-Label Clinical Trial
Eur. J. Neurol. 2021 Jan 04;[EPub Ahead of Print], M Hyodo, A Nagao, K Asano, M Sakaguchi, K Mizoguchi, K Omori, Y Tada, H Hatakeyama, N Oridate, K Naito, Y Iwata, H Shinomiya, H Hara, T Sanuki, E Yumoto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading